IP Library Granted Patent US 12,516,090
Granted Patent B2
US 12,516,090 · App. 17/221,371 · Granted Jan 6, 2026

Maltose dependent degrons, maltose-responsive promoters, stabilization constructs, and their use in production of non-catabolic compounds

Inventors: Penelope R. Chua (Emeryville, CA); Hanxiao Jiang (Emeryville, CA); Adam Leon Meadows (Emeryville, CA)
Assignee: AMYRIS, INC.
C07K14/395C12N1/16C12N15/52C12N15/635C12N15/65C12P5/02C12P5/026C12P7/64C12P19/62C12P21/00C12P21/02C07K2319/95C12N2330/51C12Y503/03002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,516,090
App. No.
17/221,371
Granted
Jan 6, 2026
Kind
B2
Abstract

The present disclosure relates to the use of a maltose dependent degron to control stability of a protein of interest fused thereto at the post-translational level. The present disclosure also relates to the use of a maltose dependent degron in combination with a maltose-responsive promoter to control gene expression at the transcriptional level and to control protein stability at the post-translational level. The present disclosure also relates to the use of a stabilization construct that couples expression of a cell-growth-affecting protein with the production of non-catabolic compounds. The present disclosure further relates to the use of a synthetic maltose-responsive promoter. The present disclosure further provides compositions and methods for using a maltose dependent degron, a maltose-responsive promoter, and a stabilization construct, either alone or in various combinations, for the production of non-catabolic compounds in genetically modified host cells.

Claims (15)

1 . A method for producing a heterologous non-catabolic compound, the method comprising:

(a) culturing a population of a genetically modified host cell in a culture medium comprising an essential compound and a carbon source comprising a maltose based inducer, wherein the genetically modified host cell comprises:

(i) a heterologous nucleic acid for producing the heterologous non-catabolic compound, wherein the heterologous nucleic acid is operably linked to a first Gal4p-responsive promoter;

(ii) a heterologous nucleic acid encoding a conditional essential gene product of a biosynthetic pathway for producing an essential compound, wherein the heterologous nucleic acid is operably linked to a second Gal4p-responsive promoter;

(iii) a nucleic acid encoding Gal4p;

(iv) a heterologous nucleic acid encoding Gal80p fused in frame to a maltose dependent degron, operably linked to a maltose-responsive promoter,

wherein the maltose based inducer in the culture medium limits the amount of the non-catabolic compound produced by the genetically modified host cell, and wherein an amount of the essential compound produced by the genetically modified host cell is limited; and

(b) culturing the population or subpopulation thereof in a culture medium comprising no added essential compound or a sufficiently low amount of the added essential compound and the carbon source wherein the maltose based inducer is absent or in sufficiently low amounts such that the activity of the maltose-responsive promoter is limited, which, in turn, increases production of the heterologous non-catabolic compound compared to step (a).

2 . The method of claim 1 , wherein the heterologous nucleic acid operably linked to the first Gal4p-responsive promoter encodes the heterologous enzymes to produce a non-catabolic compound.

3 . The method of claim 1 , wherein the heterologous nucleic acid operably linked to the first Gal4p-responsive promoter encodes an enzyme of a biosynthetic pathway for producing the heterologous non-catabolic compound.

4 . The method of claim 1 , wherein the maltose-responsive promoter is selected from the group consisting of pMAL1 (SEQ ID NO: 29), pMAL2 (SEQ ID NO: 30), pMAL11 (SEQ ID NO: 31), pMAL12 (SEQ ID NO: 32), pMAL31 (SEQ ID NO: 33), pMAL32 (SEQ ID NO: 34), pMAL32_v1 (SEQ ID NO: 78), pGMAL_v5 (SEQ ID NO: 35), pGMAL_v6 (SEQ ID NO: 36), pGMAL_v7 (SEQ ID NO: 37), pGMAL_v9 (SEQ ID NO: 38), pGMAL_v10 (SEQ ID NO: 39), pGMAL_v11 (SEQ ID NO: 40), pGMAL_v12 (SEQ ID NO: 41), pGMAL_v13 (SEQ ID NO: 42), pGMAL_v14 (SEQ ID NO: 43), pGMAL_v15 (SEQ ID NO: 44), pGMAL_v16 (SEQ ID NO: 45), pGMAL_v17 (SEQ ID NO: 46), pGMAL_v18 (SEQ ID NO: 47), pG2MAL_v1 (SEQ ID NO: 48), pG2MAL_v2 (SEQ ID NO: 49), pG2MAL_v3 (SEQ ID NO: 50), pG2MAL_v5 (SEQ ID NO: 51), pG2MAL_v6 (SEQ ID NO: 52), pG2MAL_v7 (SEQ ID NO: 53), pG2MAL_v8 (SEQ ID NO: 54), pG2MAL_v9 (SEQ ID NO: 55), pG2MAL_v10 (SEQ ID NO: 56), pG7MAL_v2 (SEQ ID NO: 57), pG7MAL_v4 (SEQ ID NO: 58), pG7MAL_v6 (SEQ ID NO: 59), pG7MAL_v8 (SEQ ID NO: 60), pG7MAL_v9 (SEQ ID NO: 61), pG172_MAL_v13 (SEQ ID NO: 62), pG271_MAL_v12 (SEQ ID NO: 63), pG721_MAL_v11 (SEQ ID NO: 64), pG712_MAL_v14 (SEQ ID NO: 65), a portion thereof that retains promoter function, and a sequence that has at least about sequence identity to thereof.

5 . The method of claim 1 , wherein the genetically modified host cell is selected from the group consisting of a fungal cell, a bacterial cell, a plant cell, and an animal cell.

6 . The method of claim 5 , wherein the genetically modified host cell is a microbial host cell.

7 . The method of claim 6 , wherein the genetically modified host cell is a yeast cell.

8 . The method of claim 7 , wherein the genetically modified host cell is Saccharomyces cerevisiae.

Assignments (6)
SECURITY INTEREST Recorded May 24, 2024
From: AMYRIS, INC.
To: EUAGORE, LLC
Reel/Frame 067528/0467 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2024
From: LAVVAN, INC.
To: AMYRIS, INC.
Reel/Frame 066953/0375 →
SECURITY INTEREST Recorded Aug 17, 2023
From: AMYRIS, INC.; AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; APRINNOVA, LLC; AMYRIS-OLINKA, LLC; ONDA BEAUTY INC.; UPLAND 1 LLC; AMYRIS ECO-FAB LLC; CLEAN BEAUTY 4U HOLDINGS, LLC; AMYRIS CLEAN BEAUTY LATAM LTDA; INTERFACES INDUSTRIA E COMERCIA DE COSMETICOS LTDA; AMYRIS BIOTECHNOLOGIA DO BRASIL LTDA; AMYRIS EUROPE TRADING B.V. (NETHERLANDS); AMYRIS BIO PRODCUTS PORTUGAL, UNIPESSOAL, LDA; BEAUTY LABS INTERNATIONAL LIMITED; AMYRIS UK TRADING LIMITED
To: EUAGORE, LLC
Reel/Frame 064619/0778 →
SECURITY INTEREST Recorded Aug 3, 2023
From: AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; AMYRIS, INC.
To: MUIRISC, LLC
Reel/Frame 064492/0518 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2022
From: CHUA, PENELOPE R.; JIANG, HANXIAO; MEADOWS, ADAM LEON
To: AMYRIS, INC.; TOTAL MARKETING SERVICES
Reel/Frame 061738/0693 →
SECURITY INTEREST Recorded Oct 18, 2022
From: AMYRIS, INC.
To: FORIS VENTURES, LLC
Reel/Frame 061703/0499 →
Continuity (4)
Division 15738918
Provisional Application 62266436 · Dec 11, 2015
Provisional Application 62184793 · Jun 25, 2015
Related Publication 20210230234A1 · Jul 29, 2021
References Cited (26)
US 20020156001A1 · Econs et al. · 2002 [cited by applicant]
US 20060141570A1 · Wood et al. · 2006 [cited by applicant]
US 20070243579A1 · Sedgwick et al. · 2007 [cited by applicant]
US 20090305342A1 · Riggs et al. · 2009 [cited by applicant]
US 20180171341A1 · Chua et al. · 2018 [cited by applicant]
EP 3313996A1 · 2018 [cited by applicant]
WO WO2010114532A1 · 2010 [cited by applicant]
WO WO2014025941A1 · 2014 [cited by applicant]
WO WO2015020649A1 · 2015 [cited by applicant]
Kisselev L., (Structure, 2002, vol. 10: 8-9. [cited by examiner]
Kwiatkowski et al., (Biochemistry 38:11643-11650, 1999. [cited by examiner]
Wristlock et al., (Quarterly Reviews of Biophysics 2003, vol. 36 (3): 307-340. [cited by examiner]
Davos et al., (Proteins: Structure, Function and Genetics, 2000, vol. 41: 98-107. [cited by examiner]
Choi et al., “Design of Protein Switches Based on an Ensemble Model of Allostery”, Nature Communications, 6:6968, Apr. 22, 2015, pp. 1-9, XP002760503, DOI: 10.1038/NCOMMS7968. [cited by applicant]
International Search Report and Written Opinion mailed on Aug. 29, 2016 for PCT/US2016/039397, 15 pages. [cited by applicant]
Dokholyan, “Controlling Allosteric Networks In ProteinS”, Chemical Reviews, vol. 116, Feb. 19, 2016, pp. 6463-6487. [cited by applicant]
Jiang et al., “Controlling Isoprenoid Production Using a Microaerobic-Responsive Switch in Yeast”, Genetics Society of America Conferences, Yeast Genetics Meeting, 2014, University of Washington, Seattle, Abstracts Book… [cited by applicant]
Makhlynets et al., “Design of Allosterically Regulated Protein Catalysts”, Biochemistry, vol. 54, Feb. 2, 2015, pp. 1444-1456. [cited by applicant]
New et al., “Different Levels of Catabolite Repression Optimize Growth in Stable and Variable Environments”, PLOS Biology, vol. 12, 2014, pp. 1-22. [cited by applicant]
Platt, “Dawn of a Golden Age Formicrobial Engineering”, World Congress on Industrial Biotechnology; Montreal, Jul. 2015, Presentation Paper, Jul. 2015, pp. 1-32, Retrieved From the Internet: URL:https://www.bio.org/site… [cited by applicant]
Sandoval et al., “Use of pantothenate as a metabolic switch increases the genetic stability of farnesene producing [cited by applicant]
Walker et al., “Mutations in maltose-binding protein that alter affinity and solubility properties”, Applied Microbiology and Biotechnology, vol. 88, 2010, pp. 187-197. [cited by applicant]
Weinhandl et al., “Carbon source dependent promoters in yeast”, Microbial Cell Factories, vol. 13, 2014, pp. 1-17. [cited by applicant]
Rienzo et al., “Different mechanisms confer gradual control and memory at nutrient- and stress-regulated genes in yeast”, Molecular and Cellular Biology, vol. 35, Aug. 17, 2015, pp. 3669-3683. [cited by applicant]
Singh RK et al. Protein Engineering Approaches in the Post-Genomic Era. 2017. Current Protein and Peptide Science. 18, 1-11. ( Year: 2017). [cited by applicant]
Zhang M et al. Propagated Perturbations from a Peripheral Mutation Show Interactions Supporting WW Domain Thermostability. 2018. Structure. 26, 1474-1485. (Year: 2018). [cited by applicant]